{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:32:11Z","timestamp":1774935131676,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jtct.2025.09.029","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T09:46:20Z","timestamp":1758620780000},"page":"98.e1-98.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Expression of HLA-B*35 is Associated With an Increased Risk of CMV Viremia and Clinically Significant CMV Infection following PTCy-Based Hematopoietic Cell Transplantation"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8093-5647","authenticated-orcid":false,"given":"Jessica S.","family":"Little","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle M.","family":"Hebert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2566-3145","authenticated-orcid":false,"given":"Donna S.","family":"Neuberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2711-5575","authenticated-orcid":false,"given":"Sarah","family":"Nikiforow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahasweta","family":"Gooptu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7622-8322","authenticated-orcid":false,"given":"Roman M.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Koreth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4627-1714","authenticated-orcid":false,"given":"Joseph H.","family":"Antin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8728-4314","authenticated-orcid":false,"given":"Corey","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Soiffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5526-4669","authenticated-orcid":false,"given":"Jerome","family":"Ritz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9077-4736","authenticated-orcid":false,"given":"Rizwan","family":"Romee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6839-3996","authenticated-orcid":false,"given":"Vincent T.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6596-0518","authenticated-orcid":false,"given":"Nicolas C.","family":"Issa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey R.","family":"Baden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5024-1713","authenticated-orcid":false,"given":"R\u00e9my","family":"Dul\u00e9ry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4175-5728","authenticated-orcid":false,"given":"Susan E.","family":"Prockop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.jtct.2025.09.029_bib0001","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood.2019000956","article-title":"How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation","volume":"135","author":"Einsele","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2025.09.029_bib0002","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/338624","article-title":"High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection","volume":"185","author":"Nichols","year":"2002","journal-title":"J Infect Dis"},{"issue":"14","key":"10.1016\/j.jtct.2025.09.029_bib0003","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1182\/bloodadvances.2023012175","article-title":"Late cytomegalovirus disease after hematopoietic cell transplantation: significance of novel transplantation techniques","volume":"8","author":"Sadowska-Klasa","year":"2024","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.jtct.2025.09.029_bib0004","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3026(23)00344-7","article-title":"Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Russo","year":"2024","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.jtct.2025.09.029_bib0005","first-page":"233.e1","article-title":"Opportunistic infections in patients receiving post-transplantation cyclophosphamide: impact of haploidentical versus unrelated donor allograft","volume":"30","author":"Little","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2025.09.029_bib0006","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1182\/blood-2023-188032","article-title":"Large-scale post-transplant TCR deep sequencing reveals a major t cell diversity bottleneck with post-transplant cyclophosphamide with implications for both efficacy and toxicity: results of the BMT CTN 1801 study","volume":"142","author":"Kean","year":"2023","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.jtct.2025.09.029_bib0007","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1182\/blood.2020009362","article-title":"Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis","volume":"137","author":"Goldsmith","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2025.09.029_bib0008","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1182\/bloodadvances.2020003005","article-title":"Impaired T- And NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide","volume":"5","author":"Rambaldi","year":"2021","journal-title":"Blood Adv"},{"issue":"25","key":"10.1016\/j.jtct.2025.09.029_bib0009","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.jtct.2025.09.029_bib0010","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1182\/blood-2009-11-251595","article-title":"High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease","volume":"115","author":"Luznik","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.09.029_bib0011","first-page":"29295","article-title":"HLA\/KIR restraint of HIV: surviving the fittest","author":"Bashirova","year":"2011","journal-title":"Annu Rev Immunol"},{"issue":"11","key":"10.1016\/j.jtct.2025.09.029_bib0012","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1056\/NEJM198909143211103","article-title":"Genetic prediction of nonresponse to hepatitis B vaccine","volume":"321","author":"Alper","year":"1989","journal-title":"N Engl J Med"},{"issue":"5408","key":"10.1016\/j.jtct.2025.09.029_bib0013","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1126\/science.283.5408.1748","article-title":"HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage","volume":"283","author":"Carrington","year":"1999","journal-title":"Science"},{"issue":"24","key":"10.1016\/j.jtct.2025.09.029_bib0014","doi-asserted-by":"crossref","first-page":"12603","DOI":"10.1128\/JVI.76.24.12603-12610.2002","article-title":"Human immunodeficiency virus type 1 (HIV-1)-specific CD8+-T-cell responses for groups of HIV-1-infected individuals with different HLA-B*35 genotypes","volume":"76","author":"Jin","year":"2002","journal-title":"J Virol"},{"issue":"23","key":"10.1016\/j.jtct.2025.09.029_bib0015","doi-asserted-by":"crossref","first-page":"12643","DOI":"10.1128\/JVI.01381-12","article-title":"Differential clade-specific HLA-B*3501 association with HIV-1 disease outcome is linked to immunogenicity of a single Gag epitope","volume":"86","author":"Matthews","year":"2012","journal-title":"J Virol"},{"issue":"6010","key":"10.1016\/j.jtct.2025.09.029_bib0016","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1126\/science.1195271","article-title":"The major genetic determinants of HIV-1 control affect HLA class I peptide presentation","volume":"330","author":"Study","year":"2010","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.jtct.2025.09.029_bib0017","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14110","article-title":"The effect of human leukocyte antigen A1 and B35-Cw4 on sustained BK polyomavirus DNAemia after renal transplantation","volume":"34","author":"Hosseini-Moghaddam","year":"2020","journal-title":"Clin Transpl"},{"issue":"1","key":"10.1016\/j.jtct.2025.09.029_bib0018","first-page":"1","article-title":"Associations between MHC class I and susceptibility to HIV-2 disease progression","volume":"5","author":"Diouf","year":"2002","journal-title":"J Hum Virol"},{"issue":"8","key":"10.1016\/j.jtct.2025.09.029_bib0019","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/blood-2009-02-206193","article-title":"Minor viral and host genetic polymorphisms can dramatically impact the biologic outcome of an epitope-specific CD8 T-cell response","volume":"114","author":"Geldmacher","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2025.09.029_bib0020","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1084\/jem.179.4.1193","article-title":"Polymorphic Hh genes in the HLA-B(C) region control natural killer cell frequency and activity","volume":"179","author":"Dubey","year":"1994","journal-title":"J Exp Med"},{"issue":"16","key":"10.1016\/j.jtct.2025.09.029_bib0021","doi-asserted-by":"crossref","first-page":"4859","DOI":"10.1182\/bloodadvances.2022007005","article-title":"Dominant epitopes presented by prevalent HLA alleles permit wide use of banked CMVpp65 T cells in adoptive therapy","volume":"6","author":"Hasan","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jtct.2025.09.029_bib0022","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2025.09.029_bib0023","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jtct.2025.09.029_bib0024","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1038\/s41409-021-01403-w","article-title":"Cytokine release syndrome after haploidentical hematopoietic cell transplantation: an international multicenter analysis","volume":"56","author":"Abboud","year":"2021","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"10.1016\/j.jtct.2025.09.029_bib0025","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount sinai acute GVHD international consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2025.09.029_bib0026","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. the 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2025.09.029_bib0027","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2025.09.029_bib0028","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1086\/339329","article-title":"Definitions of cytomegalovirus infection and disease in transplant recipients","volume":"34","author":"Ljungman","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.jtct.2025.09.029_bib0029","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/cid\/ciy696","article-title":"Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials","volume":"68","author":"Chemaly","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.jtct.2025.09.029_bib0030","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.jtct.2025.09.029_bib0031","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/imcb.12698","article-title":"Molecular insights into the HLA-B35 molecules\u2019 classification associated with HIV control","volume":"102","author":"Lobos","year":"2024","journal-title":"Immunol Cell Biol"},{"issue":"8","key":"10.1016\/j.jtct.2025.09.029_bib0032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008696","article-title":"Selective upregulation of CTLA-4 on CD8+ T cells restricted by HLA-B*35Px Renders them to an exhausted phenotype in HIV-1 infection","volume":"16","author":"Elahi","year":"2020","journal-title":"PLoS Pathog"},{"issue":"23","key":"10.1016\/j.jtct.2025.09.029_bib0033","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01259-21","article-title":"Collaboration of a detrimental HLA-B*35:01 allele with HLA-A*24:02 in coevolution of HIV-1 with T cells leading to poorer clinical outcomes","volume":"95","author":"Kuse","year":"2021","journal-title":"J Virol"},{"issue":"12","key":"10.1016\/j.jtct.2025.09.029_bib0034","doi-asserted-by":"crossref","first-page":"5894","DOI":"10.4049\/jimmunol.1302281","article-title":"CD8 T cell\u2013evasive functions of human cytomegalovirus display pervasive MHC allele specificity, complementarity, and cooperativity","volume":"192","author":"Ameres","year":"2014","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.jtct.2025.09.029_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-022-05000-9","article-title":"Viral immune evasins impact antigen presentation by allele-specific trapping of MHC I at the peptide-loading complex","volume":"12","author":"Sethumadhavan","year":"2022","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.jtct.2025.09.029_bib0036","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.3324\/haematol.2022.280685","article-title":"Cytomegalovirus-specific T cells restricted for shared and donor human leukocyte antigens differentially impact on cytomegalovirus reactivation risk after allogeneic hematopoietic stem cell transplantation","volume":"108","author":"Tassi","year":"2023","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.jtct.2025.09.029_bib0037","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/s41423-024-01186-2","article-title":"Immune surveillance of cytomegalovirus in tissues","volume":"21","author":"Mihali\u0107","year":"2024","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"10.1016\/j.jtct.2025.09.029_bib0038","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/cid\/ciae535","article-title":"Current and future strategies for the prevention and treatment of cytomegalovirus infections in transplantation","volume":"81","author":"Heldman","year":"2025","journal-title":"Clin Infect Dis"},{"issue":"23","key":"10.1016\/j.jtct.2025.09.029_bib0039","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1182\/blood-2008-10-143560","article-title":"How I treat cytomegalovirus in hematopoietic cell transplant recipients","volume":"113","author":"Boeckh","year":"2009","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.jtct.2025.09.029_bib0040","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jtct.2025.09.029_bib0041","first-page":"707","article-title":"American Society for Transplantation and Cellular Therapy series: #3-prevention of cytomegalovirus infection and disease after hematopoietic cell transplantation","volume":"27","author":"Hakki","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"9","key":"10.1016\/j.jtct.2025.09.029_bib0042","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1093\/cid\/ciz1210","article-title":"Cytomegalovirus (CMV) cell-mediated immunity and CMV infection after allogeneic hematopoietic cell transplantation: The REACT study","volume":"71","author":"Chemaly","year":"2020","journal-title":"Clin Infect Dis"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725014538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725014538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T17:57:22Z","timestamp":1773165442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725014538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2666636725014538"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.09.029","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expression of HLA-B*35 is Associated With an Increased Risk of CMV Viremia and Clinically Significant CMV Infection following PTCy-Based Hematopoietic Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.09.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}